Anti-PD-1 therapy plus chemotherapy (immunochemotherapy) has become standard first-line treatment for high PD-L1-expressing advanced esophageal squamous cell carcinoma (ESCC). Here, CD274 is linked to esophageal squamous cell carcinoma.